1. Home
  2. KNOP vs NGNE Comparison

KNOP vs NGNE Comparison

Compare KNOP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KNOT Offshore Partners LP

KNOP

KNOT Offshore Partners LP

HOLD

Current Price

$11.04

Market Cap

349.7M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$31.90

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNOP
NGNE
Founded
2013
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
349.7M
327.8M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
KNOP
NGNE
Price
$11.04
$31.90
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
N/A
$63.57
AVG Volume (30 Days)
81.2K
170.3K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.51
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.16
$14.65
52 Week High
$11.55
$37.27

Technical Indicators

Market Signals
Indicator
KNOP
NGNE
Relative Strength Index (RSI) 60.09 70.41
Support Level $10.04 $19.40
Resistance Level N/A $32.02
Average True Range (ATR) 0.30 2.05
MACD 0.04 0.36
Stochastic Oscillator 66.85 79.36

Price Performance

Historical Comparison
KNOP
NGNE

About KNOP KNOT Offshore Partners LP

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: